Skip to main content
. Author manuscript; available in PMC: 2020 Aug 7.
Published in final edited form as: Blood. 2018 Jun 14;132(7):694–706. doi: 10.1182/blood-2017-10-810739

Figure 1. Clinical courses of 4 patients who developed aggressive B-cell lymphomas during JAK1/2 inhibition.

Figure 1

Timelines (A-D). Frequencies of immunoglobulin rearrangement in the bone marrow during myelofibrosis and lymphoma development in conventionally treated patients (N 5 44) compared with patients treated with JAK1/2 inhibitor (N = 54) (E). NHL, non-Hodgkin lymphoma; CR, complete remission; CRu, complete remission unconfirmed; rNHL, remission of NHL; sAML, secondary acute myeloid leukemia.